Video & Transcript : 'FDA user fees' :

Page 52 of 500
MA

Massachusetts 2025-2026 Regular Session

Senate Session (Full Formal with Calendar) Jun 18th, 2026

Massachusetts Senate Floor Meeting

Transcript Highlights:
  • They're going to enter into a contract, usually with a monthly fee for the services of that physician
  • utilization review organizations from using prior authorization that restricts or delays access to FDA-approved
  • It restricts and delays access to FDA-approved medications for the treatment of serious mental illness
  • This amendment ensures that when a clinician prescribes an FDA-approved medication to treat SMI, an insurer
AZ

Arizona 2026 Regular Session

02/03/2026 - House Commerce

Commerce

Transcript Highlights:
  • Our point is that this isn't an ATM fee because users, like other people have testified, use it two dozen
  • More than 9 in 10 users say they understand the service structure and associated fees, and a strong majority
  • All potential fees are represented to users clearly and transparently.
  • Users who cancel their EWA service may not be sent to collections, charged interest, or late fees, and
  • Users who cancel their EWA service may not be sent to collections, charged interest, or late fees, and
WA

Washington 2025-2026 Regular Session

Senate Housing Jan 30th, 2026 at 10:30 am

Housing

Transcript Highlights:
  • tenant toward rent before applying any payment toward late payments, damages, legal costs, or other fees
  • , including attorney fees.
  • due under the lease, up to $75 in total, and any attorney’s fees awarded by the court.
  • They're falling behind because rents have jumped 10% or more and junk fees are piling on top.
  • And since we're not recapturing the legal fees ...or the process service fees through this process, we're
Committee: Senate Housing
TX

Texas 89th Regular

89th Legislative Session Apr 14th, 2025

Texas House Floor Meeting

Transcript Highlights:
  • HB number 290 by Lopez-Auberre relating to assistance for tuition and fees at post-secondary educational
  • granting a limited power of eminent domain providing authority to issue bonds writing authority to impose fees
  • District number one providing authority to issue bonds, providing authority to impose assessments, fees
  • limited power of eminent name providing authority to issue bonds writing authority to impose assessment fees
TX

Texas 89th Regular

Natural Resources Mar 26th, 2025

Natural Resources

Transcript Highlights:
  • I guess in this particular case, it's no fault of the users of that system, right?
  • So it wouldn't necessarily be the users' issue unless they have to pay for it in the form of a large
TX

Texas 89th Regular

Natural Resources Mar 26th, 2025

Natural Resources

Transcript Highlights:
  • Let's just assume those for all new residences, and you have a minimum rate fee, a minimum amount of
  • And then the next step is to deliver it to users, correct?
  • I think as users and consumers, as you guys are, resources to deal with these leaking pipes.
  • This bill would remove the question of interlocal agreements in Chapter 36 for the use of these fees
  • To serve all users that experience water loss.
FL

Florida 2025 Regular Session

October 8, 2025 - 10:30 AM

Transcript Highlights:
  • And just to provide some context as to what that is on the fee for service side, a lot of payments are
  • So on the fee for service side, you have an up or payment limit.
  • And we also used CMS is clinical laboratory fees schedule as well as our own Florida Medicaid, a fee
  • The average we fee schedule from 243 biomarkers to 632.
  • So in terms of as you can see for a fee for service, there's there's limited paid claims.
NV

Nevada 2025 Regular Session

Senate Floor Session May 29th, 2025 at 11:00 am

Nevada Senate Floor Meeting

Transcript Highlights:
  • It requires various fees, assessments, and taxes collected pursuant to provisions governing captive insurers
  • The amendment removes most provisions of the bill except those increasing certain fees and authorizing
  • The amendment removes most provisions of the bill except those increasing certain fees and authorizing
  • Increases certain fees relating to emissions testing.
  • products are exempt. ...strains state resources, as only 34 FDA-authorized products exist.
HI
Transcript Highlights:
  • </c><01:29:30.320><c> that</c><01:29:30.480><c> fees</c> down so do the special fee that fees down so
  • do the special fee that fees into<01:29:31.199><c> our</c><01:29:31.520><c> special</c><01:29:31.800
  • People have the right to use FDA-authorized products.
  • People have the right to use FDA-authorized products.
  • People have the right to use FDA-authorized products.
Summary: The joint hearing covered HB 553 on biomarker testing coverage, HB 556 on colorectal cancer screening access, and later HB 712 on 340B drug pricing. For HB 553, the American Cancer Society Cancer Action Network, patient advocates Natalie Heyman and Susan Hirano, a surgical oncologist, and the American Lung Association strongly supported the bill, arguing that biomarker testing should be covered when ordered by a doctor and guided by current evidence. DHS and several insurers offered comments and requested amendments, with DHS saying it appreciated the intent but wanted changes. The committees then voted to pass HB 553 with amendments, including a House draft and a defective date of July 1, 3000; both the House Health and Human Services and Homelessness committees adopted the recommendation unanimously. For HB 556, testimony focused on closing gaps in colorectal cancer screening, especially for uninsured and underinsured patients who can get stool-based screening but then cannot access follow-up colonoscopies. Community Clinic of Maui, ACS CAN, and the American Cancer Society supported the bill, with ACS CAN urging a program similar to the breast and cervical cancer control program and offering amendments. DHS requested that the program and appropriation not conflict with executive budget priorities, and the committees noted technical amendments, a defective date, a blank appropriation amount, and corrections changing Medicare references to Medicaid. HB 556 was also passed with amendments by both committees. The hearing then moved to HB 712 on 340B drug pricing and contract pharmacies. The Department of Health and the Attorney General’s office expressed concern that the bill would require the state to regulate private commercial activity and said the department lacked the expertise and resources to implement it as written, suggesting it might belong in a different statutory section. In contrast, PhRMA opposed the bill, while Hawaii Pacific Health and Hawaii Island Community Health Center supported it, saying 340B savings are important for hospital services and patient access to low-cost medications, especially where manufacturers have restricted shipments to contract pharmacies. No vote on HB 712 was taken in the portion provided.
LA

Louisiana 2026 Regular Session

House of Representatives Mar 24th, 2026

Louisiana House Floor Meeting

Transcript Highlights:
  • fees.
  • fees.
  • for a decrease in fees to increase grace periods.
  • The Louisiana Tax Commission has some self-generated fees.
  • We're looking to extend that fee until 2030.
AZ

Arizona 2026 Regular Session

01/21/2026 - Senate Health and Human Services

Senate Health and Human Services COR

Transcript Highlights:
  • Doctors, one of my questions is this: Is this radiation protection system regulated by the FDA?
  • These are all FDA-cleared devices, yes. Thank you, Madam Chair.
  • One of the, one of my questions is this radiation protection system, is it regulated by the FDA?
  • These are all FDA cleared devices, yes. Thank you. Madam Chair, doctors.
  • And this will also revert back to being subject to the cap fee-for-service schedule and not the MCOs.
Summary: The committee heard a series of bills and public testimony, beginning with introductions and then taking up several health and human services measures. A major focus was SB 1120 and SB 1121, which address radiation protection in cardiac catheterization and other ionizing-radiation procedure rooms. SB 1120 would require health care facilities to equip at least 50% of procedure rooms with radiation protection systems by July 1, 2027, while SB 1121 would prohibit requiring lead aprons in rooms with such systems and instead require real-time dosimeters for staff who opt out of lead aprons. Physicians, nurses, and a hospital executive testified that enhanced radiation protection systems can dramatically reduce occupational exposure, lower cancer and orthopedic risks, and help with workforce recruitment and retention; a hospital alliance remained neutral pending further stakeholder discussions. Both bills were amended and passed out of committee on 7-0 votes, and SB 1118, which appropriates state funds for a rural hospital grant program to install radiation protection systems, also passed 7-0. The committee also approved SB 1001, which appropriates $1 million to the Department of Economic Security for the Older Individuals Who Are Blind program, after testimony from blind and low-vision Arizonans and advocates describing long waitlists, the need for independent living training, and the program’s role in preventing unnecessary dependence. SB 1072, a major funding bill for home- and community-based services and room-and-board rate increases for individuals with intellectual and developmental disabilities, drew testimony from providers about severe staffing shortages, overtime, turnover, and underfunding; it passed 6-0 with one not voting. SB 1125, requiring DCS to pursue MOUs with tribes and improve tribal communication and access to licensing and enforcement information, also passed 6-0 with one not voting. The committee then considered SB 1123, which removes a board-certification requirement so trained forensic pathologists can supervise autopsy training for residents and fellows; Maricopa County supported it as a workforce and training fix, and it passed 6-0 with one not voting. SB 1052, allowing mild hyperbaric oxygen therapy in assisted living facilities under physician order and DHS rules, generated mixed testimony: supporters argued it could improve health and independence for residents, while opponents raised concerns about off-label treatment in nonmedical settings. The bill passed 5-2. SB 1112, which reduces the number of acquaintance witnesses required in court-ordered treatment proceedings from two to one and allows the court to waive the witness requirement under certain conditions, drew strong testimony from families and mental health advocates on both sides; it passed 5-2. The committee also began hearing SB 1113, which would allow certain service of process in court-ordered evaluation and treatment cases by evaluation-agency employees or other court-authorized persons, but the transcript cuts off before final action on that bill.
TX

Texas 89th Regular

Health Care Affordability, Select May 1st, 2026

Health Care Affordability, Select

Transcript Highlights:
  • They do not want to do traditional fee-for-service; they only want to do value-based payment.
  • They were essentially our means of determining what drugs that have been FDA-approved should... ...means
  • of determining what drugs that have been FDA-approved should be available to patients.
  • But I will say to your point, yes, they pay them quickly unless they claw it back with DIR fees.
  • And so that's why I've listed the fee-for-service model here.
MN

Minnesota 2025-2026 Regular Session

Department of Agriculture update 2/18/26

Minnesota House Floor Meeting

Transcript Highlights:
  • You know, general funds are about 38%, dedicated funds from fees and everything is 35%.
  • services, APHIS, which works with the plant and animals, FSIS, which is our food safety inspection, FDA
  • </c><00:03:25.920><c> and</c><00:03:26.159><c> everything</c> dedicated funds from fees and everything
  • dedicated funds from fees and everything is<00:03:26.879><c> 35%</c><00:03:28.319><c> legacy</c><00:
  • So just wanted to remind folks that the fee would not turn into $8 million as well.
MA

Massachusetts 2025-2026 Regular Session

Joint Committee on Education Jun 21st, 2026 at 11:00 am

Joint Committee on Education

Transcript Highlights:
  • That’s thanks to science-based oversight by the FDA.
  • Banning FDA-approved ingredients will make it harder for schools to offer affordable, nutritious, and
  • So I understand your argument is that, you know, we have federal FDA and USDA guidelines for schools
  • And we trust the FDA and its science-based approach.
  • Most of those teens were not regular drug users.
Summary: The Joint Committee on Education held a public hearing on a large slate of bills, with the chairs emphasizing time limits, written testimony, and grouping similar measures together. Early testimony focused on opioid use disorder education in schools (S.382), with Senator Keenan arguing that students should be taught about the risks of substance use disorder and naloxone use as part of health curricula. Representative DeCost also briefly introduced H.551, a narrow bill concerning parent rights for children in third grade and younger. Several bills were then closed without testimony, including measures on type 1 diabetes informational materials and other diabetes-related proposals. A major portion of the hearing centered on school health and emergency response bills. Supporters of H.652/S.342 on diabetes management in schools described inconsistent district practices and urged clearer standards so students can receive care in classrooms rather than being sent out of instruction. Bills on epinephrine access and seizure disorders drew extensive testimony: advocates for stock epinephrine in schools argued that unassigned epinephrine can save lives and should be funded in a cost-neutral way, while a pediatrician opposed one version as an unfunded mandate. For seizure-safe schools (S.422/H.635), students, parents, educators, and advocates described missed or delayed responses to seizures, stigma, and the need for staff training, seizure action plans, and emergency medication protocols. A separate bill, H.645, allowing anti-seizure medication on school buses, was supported by a parent and student who said current law forces costly and restrictive transportation arrangements. The committee also heard testimony on youth skin health bills (S.334/H.600/H.619), which would let students carry and apply sunscreen at school and camp without a physician’s note. Supporters from melanoma prevention, dermatology, and industry groups said the bills would remove unnecessary barriers and promote sun-safe habits, while one witness cautioned about drafting details and unintended consequences. The hearing then moved to CPR/AED education for graduation (S.456), where Senator Tarr, a student advocate, and the Red Cross all supported requiring hands-on CPR certification for high school students. Finally, the committee took testimony on healthy school lunches (H.539/S.401): supporters from the Healthy School Lunch Coalition and school food directors backed stronger nutrition standards and a standing advisory council, while Consumer Brands Association witnesses opposed the bill as too vague and potentially disruptive. A nutrition scientist also warned about unintended restrictions on medically necessary or innovative foods. The chairs closed the hearing on the healthy lunch bills and then opened testimony on universal school meals for virtual schools (H.700), with Superintendent Patrick Latuka supporting access for students in Commonwealth virtual schools who currently receive no meal support.
FL

Florida 2026 4th Special Session

January 27, 2026 - 03:00 PM

Transcript Highlights:
  • pricing set by the federal government, CMS plus 4% for administrative overcharge, and the dispensing fee
  • On average, it is a two- to three-year delay for approval compared to approval by the FDA, if that is
  • AVERAGE IT IS A 2 TO 3 YEAR DELAY FOR AN&nbsp;&nbsp; 491 APPROVAL THAN IT IS TO HAVE APPROVAL TO THE FDA
  • If we pay PBMs based on a fee or a fixed rate versus the list price of medicines, you should see more
Summary: The committee first took up CS/House Bill 981, which would restore the Ocklawaha River and related natural resources. Supporters, including environmental groups, Save the Manatee Club, business owners, and Reunite the Rivers advocates, argued the bill would improve manatee habitat, fish passage, flood protection, tourism, and long-term economic returns while reducing dam maintenance costs. Opponents and skeptics focused on concerns about water quality, nutrient loading in the St. Johns River, loss of the Rodman Reservoir’s habitat and water-supply value, and potential ecological and economic harms. Members in debate largely supported the restoration effort, and the bill was reported favorably on a unanimous vote. The committee then heard HB 697, the PRICE Act, which would use international reference pricing to set a drug cost benchmark, address pharmacy benefit manager practices, and require health plans to keep drug prices stable for the year. The sponsor said the bill would lower costs and improve access, especially for uninsured Floridians. Supporters, including independent pharmacists, argued PBMs are squeezing pharmacies and that the bill could help lower prices. Opponents from BioFlorida and PhRMA warned the proposal could disrupt the national drug supply chain, fail to pass savings to patients, and lead to shortages, reduced access, and less innovation. After debate, the bill passed favorably, with Rep. Chambliss voting no. The committee also considered CS/HB 1081, which was amended to include private colleges and universities with NCA designation in the program. After brief discussion and support from United Way Miami, the committee reported the bill favorably. Finally, CS/HB 177 was introduced as a framework for Florida’s regional councils to cross-assign bills among regions; it received supportive testimony and was also reported favorably. The meeting then adjourned.